Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tryptic Tablets of Aspergillus oryzae for pancreatic exocrine insufficiency
ChiCTR2000032976Phase 4Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Jun 2020
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Aspergillus oryzae in exocrine pancreatic insufficiency (EPI) (3 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoint: Dyspepsia Symptom Score. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
Aspergillus oryzae
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on ChiCTR2000032976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032976.